HBOT and Long COVID: What the Emerging Research Shows

Few conditions have generated as much interest in hyperbaric oxygen therapy as long COVID. The combination of debilitating symptoms, limited treatment options, and a patient population that is often highly motivated to find solutions has made HBOT one of the more widely discussed interventions in post-viral recovery circles.

The research is early. But it is more substantive than much of what circulates online, and it is worth examining carefully.

What Long COVID Does to the Body

Long COVID, the persistence of symptoms beyond the acute phase of a SARS-CoV-2 infection, is not a single condition. It is a cluster of overlapping syndromes that can include profound fatigue, cognitive impairment (commonly called brain fog), breathlessness, sleep disturbance, pain, and autonomic dysfunction.

The mechanisms driving these symptoms are still being worked out. Several lines of evidence point toward microclots in small blood vessels, persistent neuroinflammation, mitochondrial dysfunction, and impaired oxygen delivery to tissues, particularly in the brain and peripheral nervous system.

This is where the theoretical rationale for HBOT becomes relevant. If a meaningful component of long COVID symptoms is driven by tissue hypoxia and vascular dysfunction, then a therapy that dramatically increases dissolved oxygen in plasma, bypassing haemoglobin and reaching tissues through diffusion, has a plausible mechanism of action.

The Research So Far

The most significant published study to date is a randomised controlled trial from Tel Aviv University, published in 2022 in the journal Nature Communications. Seventy-three long COVID patients were randomised to either 40 sessions of HBOT at 2.0 ATA with 100% oxygen, or a sham procedure. The HBOT group showed statistically significant improvements in cognitive function, energy, sleep quality, and pain compared to the sham group. Brain imaging showed measurable changes in cerebral blood flow and neural activity.

This is a single trial with a relatively small sample. It has not yet been replicated at scale. But it is a properly designed randomised controlled trial, not an anecdote or a case series, and its findings are consistent with the proposed mechanisms.

Several other trials are underway in the United States, Europe, and Israel. The picture will become clearer over the next two to three years as results accumulate.

What the current evidence does not support is certainty. Long COVID is heterogeneous, different patients have different underlying drivers, and it is unlikely that HBOT will be equally effective across all presentations. Identifying which patients are most likely to respond, and at what point in their illness, is work that still needs to be done.

What a Course of Treatment Looks Like

The protocols used in long COVID research have generally involved 40 sessions at 2.0 ATA, breathing 100% oxygen, with each session lasting 90 minutes. Sessions are typically delivered daily on weekdays over eight weeks.

This is a substantial commitment. For patients who are already fatigued and struggling with daily function, the logistics of attending a clinic five days a week for two months is not trivial. Some patients report a temporary increase in fatigue in the early sessions before improvement begins, a pattern that has been observed in other HBOT applications and is thought to reflect the physiological adjustment to repeated hyperoxygenation.

As with all HBOT applications, the clinical decisions about whether a patient is a suitable candidate, what pressure and duration to use, and how to monitor progress belong to the treating physician. HBOT is contraindicated in certain conditions, and a thorough medical assessment before beginning treatment is not optional.

The Honest Limitations

Long COVID research is moving quickly, and the HBOT literature is no exception. But several limitations are worth naming directly.

Most published studies are small. The Tel Aviv trial had 73 participants. Larger trials are needed before HBOT can be considered a standard of care for long COVID rather than a promising experimental intervention.

Patient selection in the published research has not always been consistent. Long COVID encompasses a wide range of presentations, and it is not yet clear whether the benefits observed in trials generalise to all patients who identify as having long COVID.

Access to hard shell HBOT at the pressures used in research is not universal. Soft shell chambers at 1.3 ATA are not a meaningful approximation of the protocols studied. Patients who pursue HBOT for long COVID in a soft shell chamber at home are not replicating the research conditions, and should not expect equivalent outcomes.

Cost is a real barrier. A 40-session course of HBOT at a private clinic can represent a significant financial commitment, and insurance coverage for long COVID HBOT is limited in most jurisdictions. Patients considering treatment should understand the full cost before beginning, including what happens if they need additional sessions.

Who Is Pursuing This Treatment

People who pursue HBOT for long COVID tend to share a common profile: they have been symptomatic for months or years, they have exhausted conventional options, and they have done enough research to understand that HBOT is not a guaranteed solution but represents a credible avenue worth exploring seriously.

Many are professionals, people whose cognitive function is central to their work and whose symptoms have had a measurable impact on their capacity to function. The brain fog and fatigue of long COVID are not abstract complaints; for many patients they represent a significant disruption to professional and personal life.

For this group, the question is not whether HBOT is worth considering, the research suggests it is, but how to access treatment at the right standard, with appropriate medical oversight, at a facility that has genuine experience with post-viral presentations.

Navigating Access

Hard shell HBOT for long COVID is available through specialist hyperbaric centres internationally and across Europe. Quality varies considerably. Some facilities have developed specific long COVID protocols and have clinical staff with experience in post-viral presentations. Others are offering HBOT as a general wellness service without the clinical infrastructure to properly assess and monitor patients with complex post-viral illness.

The difference matters. A patient with long COVID who is also managing cardiovascular complications, autonomic dysfunction, or significant psychiatric comorbidities needs a different level of clinical oversight than a healthy athlete using HBOT for recovery.

If you are considering HBOT for long COVID, for yourself or someone you are supporting, understanding the landscape before you commit to a clinic and a course of treatment is time well spent. The right facility, the right protocol, and the right clinical team are not interchangeable with the nearest available option.